TLDR:
- Canaan has added Uwe Schoenbeck, Ph.D. to its healthcare investment team as a new Venture Partner.
- The firm has raised over $1 billion since early 2023 to support biopharma and technology investments.
Canaan, a venture capital firm, has announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck brings more than 25 years of experience in the science and healthcare industry, as well as academia, to the team. He has a strong background in identifying breakthrough science, deal making, and venture investing, aligning well with Canaan’s vision for creating transformational companies.
Dr. Schoenbeck’s expertise and track record make him a valuable asset in driving new investments and company creation from Canaan XIII, the firm’s latest fund. With a background in enabling and translating emerging science into breakthrough therapies, he will support Canaan’s biopharma portfolio and seek new opportunities to advance patient care.
In addition to adding Dr. Schoenbeck to the team, Canaan has also raised more than $100 million in new capital to bolster its biopharma investment efforts. This brings the total funds raised by the firm since early 2023 to over $1 billion, with a significant portion allocated to healthcare and technology investments. The firm aims to support visionary entrepreneurs and create transformational companies that address significant unmet needs in healthcare and technology sectors.
Canaan XIII focuses on the creation of biopharmaceutical and therapeutics companies, prioritizing areas with high unmet clinical needs such as oncology, immunology, and neurology. The team aims to drive impactful new medicines through genetically defined precision approaches that can improve patient care and outcomes.
